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Abstract 
Aims 
Pre-existing diabetes is associated with an increased risk of stillbirth but few studies have excluded the effect of 
congenital anomalies. This study used data from a long-standing population-based survey of women with pre-
existing diabetes to investigate the risks of fetal and infant death and quantify the contribution of glycaemic 
control. 
 
Methods 
All normally-formed singleton offspring occurring in women with pre-existing diabetes (n=1206 with type 1 
diabetes and n=342 with type 2 diabetes) in the North of England during 1996-2008 were identified from the 
1RUWKHUQ'LDEHWHVLQ3UHJQDQF\6XUYH\5HODWLYHULVNV55VRI IHWDOGHDWKZHHNV
JHVWDWLRQDQG LQIDQW
death were estimated by comparison with population data from the Northern Perinatal Morbidity and Mortality 
Survey. Predictors of fetal and infant death in women with pre-existing diabetes were examined by logistic 
regression. 
 
Results  
The prevalence of fetal death in women with diabetes was over four times greater than among those without 
[RR=4.56 (95% confidence interval, CI: 3.42, 6.07) p<0.0001], while for infant death it was nearly doubled 
[RR=1.86 (95% CI: 1.00, 3.46) p=0.046]. There was no difference in the prevalence of fetal death (p=0.51) or 
infant death (p=0.70) between women with type 1 diabetes and women with type 2 diabetes. There was no 
evidence that the RR of fetal and infant death had changed over time (p=0.95).  
 
Increasing peri-conception HbA1c above 49mmol/mol (6.6%) [adjusted odds ratio, aOR=1.02 (95% CI: 1.00, 1.04) 
p=0.01], pre-pregnancy retinopathy [aOR=2.05 (95% CI: 1.04, 4.05) p=0.04] and lack of pre-pregnancy folic acid 
consumption [aOR=2.52 (95% CI: 1.12, 5.65) p=0.03] were all independently associated with increased odds of 
fetal and infant death.  
 
Conclusions 
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Pre-existing diabetes is associated with a substantially increased risk of fetal and infant death in normally-formed 
offspring, the effect of which is largely moderated by glycaemic control.  
 
Keywords 
Diabetes mellitus, HbA1c, pregnancy, miscarriage, stillbirth, neonatal death 
 
 4 
Abbreviations 
aOR  Adjusted odds ratio 
CI  Confidence interval 
IQR  Interquartile range 
HbA1c  Glycated haemoglobin 
LOWESS Locally-weighted scatterplot smoothing 
NorCAS Northern Congenital Abnormality Survey 
NorDIP  Northern Diabetes in Pregnancy Survey 
PMMS  Perinatal Morbidity and Mortality Survey 
OR  Odds ratio 
RR  Relative risk 
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Introduction 
Diabetes is one of the most common pre-existing maternal conditions complicating pregnancy. Affecting 0.5-2% 
of pregnancies, the prevalence is rising as a consequence of the obesity epidemic and increases in maternal age. 
This has considerable implications, since pre-existing diabetes (both type 1 and type 2) is associated with a range 
of pregnancy complications, including increased risks of macrosomia, congenital anomaly, and delivery by 
caesarean section[1-3]. It has long been observed that pre-existing diabetes is also associated with an increased 
risk of stillbirth[4], although there is heterogeneity in the estimated relative risk (RR)[5].  
 
Pre-pregnancy care, particularly focussing on optimising glycaemic control, improves birth outcomes in women 
with pre-existing diabetes[6]. With intensive support, some women with diabetes can achieve similar outcomes 
to those without[7], an unmet goal of the St Vincent declaration[8]. It is uncertain, however, whether such 
improvements can be achieved in routine clinical care. Observational studies from the last 20 years have not 
shown any reduction in the RR of fetal death[9-18], despite guidelines advising women with pre-existing diabetes 
to achieve good glycaemic control before pregnancy[19, 20].  
 
There is a paucity of data on the risks of fetal and infant death independent of congenital anomaly, and the 
contribution of glucose control and other clinical and socio-demographic factors are poorly described. We used 
unique data from several long-standing population-based registers in the North of England to investigate the 
association between pre-existing diabetes and the risks of fetal and infant death in normally-formed offspring, and 
to quantify the contribution of glycaemic control.  
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Methods 
The Northern Diabetes in Pregnancy Survey (NorDIP) 
The North of England (UK) is a geographically distinct area with a population of three million and approximately 
32,000 births per year (see Supplementary Figure 1). The NorDIP records details of all pregnancies occurring 
in women resident in the region and diagnosed with (type 1 or type 2) diabetes at least six months before 
conception. Pregnancies in women with gestational diabetes (i.e. hyperglycaemia first diagnosed during 
pregnancy) are not included. Clinicians working within the region's nine units collect and supply information on 
a range of clinical and sociodemographic variables, including maternal glycated haemoglobin concentration 
(HbA1c) pre-conception, in the first trimester, and in the third trimester. For further details see Glinianaia et al[1]. 
 
Study sample 
This study includes data on all singleton pregnancies occurring in women with pre-existing diabetes delivered at 
or after 20 completed weeks' of gestation between 01 January 1996 and 31 December 2008. Pregnancies 
complicated by major congenital anomalies, which have previously been shown to be associated with both pre-
existing diabetes and the risk of fetal and infant death[2, 21], were identified from the Northern Congenital 
Abnormality Survey (NorCAS) and excluded. The NorCAS is a long-standing population-based register of 
congenital anomaly that collects data on all cases of congenital anomaly occurring in all deliveries in the North 
of England, irrespective of maternal diabetes status (for further details see Bell et al[2]). The total number of 
singleton live births and fetal and infant deaths were obtained from the UK Office for National Statistics 
(www.statistics.gov.uk) and the Northern Perinatal Morbidity and Mortality Survey (PMMS)[22] respectively. 
The number of normally-formed offspring was determined by subtracting the number of NorCAS registrations.  
 
Definitions 
Late miscarriages are the spontaneous loss of a fetus at 20-23 completed weeks of gestation. Stillbirths are 
deliveries of a fetus showing no signs of life at 24 or more completed weeks of gestation. Late stillbirths are 
stillbirths at 28 of more completed weeks of gestation. Antepartum stillbirths are stillbirths where the fetus died 
before the onset of labour. Intrapartum stillbirths are stillbirths where the fetus after the onset of labour. Fetal 
deaths comprise late miscarriages and stillbirths. Neonatal deaths are deaths, following live birth, within the first 
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28 days of life. Postneonatal deaths are deaths, following live birth, of an infant aged 28 days or more, but less 
than one year. Infant deaths comprise neonatal deaths and postneonatal deaths.  
 
Analysis 
Prevalence rates were estimated per 1000 births and late miscarriages, for fetal outcomes, and per 1000 live births, 
for infant outcomes. 95% confidence intervals (CIs) for prevalences were estimated using the Clopper-Pearson 
(Exact) method. RRs were calculated by comparing the prevalences among women with pre-existing diabetes to 
the prevalence among the remaining population. To examine whether the RR for fetal and infant death had 
changed over time, a cross-product interaction between diabetes status and year of delivery was evaluated within 
a Poisson regression model. RRs for fetal death at specific gestational ages were estimated using the 'fetuses-at-
risk' approach[23]. In each period, the proportion of cases from the total number of on-going pregnancies (i.e. 
containing fetuses 'at risk of fetal death') was compared. The number of on-going pregnancies at each gestational 
age was estimated from a reference UK population[24].  
 
Odds ratios (ORs) and 95% CIs for all variables with hypothesised influences on fetal and/or infant death were 
analysed in relation to fetal death, late stillbirth, infant death, fetal and infant death combined, and late stillbirth 
and infant death combined within a series of logit-linked generalised estimating equations. Between-mother 
variation was modelled as a random-intercept to account for the non-independence of repeat pregnancies in the 
same woman. Peri-conception HbA1c was defined as the closest measurement within three months prior to the last 
menstrual period (available for 48.8% of pregnancies) or mean first trimester measurement (<14 weeks' gestation) 
(available for 86.0% of pregnancies) for women with no pre-conception measurement. Peri-conception HbA1c 
was chosen as a reasonable surrogate of pre-conception HbA1c, as first trimester HbA1c was highly correlated with 
pre-conception HbA1c (Spearman's correlation coefficient=0.76). Third-trimester HbA1c was examined only in 
relation to deliveries at 28 weeks' gestation. Adjusted ORs were estimated using a backwards stepwise approach; 
all variables were entered into the model and non-significant ones were removed iteratively, by decreasing p-
value, until only those with p<0.1 remained. Cross-product interaction terms were used to explore whether the 
effect of each variable with a significant independent association on the risk of fetal and infant death varied by 
diabetes type. The relationships between peri-conception and third trimester HbA1c with the risks of fetal and 
infant death were explored by locally-weighted scatterplot smoothing (LOWESS)[25]. LOWESS produces 
 8 
smoothed estimates of the association between two variables without requiring a priori specification. Since J-
shaped associations were observed between both variables and the risk of fetal death, all models of fetal death or 
fetal and infant death combined were modelled by piecewise linear regression with knots at the lowest LOWESS 
values [49mmol/mol (6.6%) for peri-conception HbA1c and 43mmol/mol (6.1%) for third trimester HbA1c]. 
LOWESS was also used to estimate the absolute risks of fetal death, stillbirth, late stillbirth, and infant death for 
selected categories of peri-conception and third trimester HbA1c by averaging the modelled risk for all values 
within that category (with CIs being estimated by bootstrapping from 10,000 subsamples). Logit-linked 
generalised estimating equations were used to estimate the absolute risk of late stillbirth for selected categories of 
peri-conception and third trimester HbA1c simultaneously by evaluating the model at the category-specific means 
(with CIs being estimated using the delta method[26]). Due to instability at the LOWESS tails, only categories 
within the 5th and 95th centile of case values are reported. Participants with missing data were excluded from 
individual analyses by casewise deletion. Analyses were performed using Stata 11.1 (Statacorp, TX, USA). 
P<0.05 was considered statistically significant. 
 
Ethics approval and research governance  
Newcastle Research Ethics Committee originally granted approval for the NorDIP in 1993. Data are now obtained 
and held with informed consent. 
 
Role of the funding source 
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the 
manuscript. The views expressed in this manuscript are entirely those of the authors and do not necessarily those 
of the funders. 
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Results 
Figure 1 shows the derivation of the study sample. Overall, 397,392 singleton live births, stillbirths and late 
miscarriages uncomplicated by major congenital anomalies were identified during the study period, including 
1,548 in women with pre-existing diabetes, a prevalence of 3.9 (95% CI: 3.7, 4.1) per 1,000 deliveries. Descriptive 
statistics for pregnancies affected by pre-existing diabetes are shown in Supplementary Tables 1 and 2. 53% 
involved male fetuses, 41% were primiparous, and 94% of women were white. The median maternal age was 30 
years (interquartile range, IQR=25-34) and the median body mass index was 27kg/m2 (IQR=24-32). 24% of 
women were recorded as smoking during pregnancy and 32% as taking folic acid pre-pregnancy. 78% had type 1 
diabetes and 22% type 2. The median peri-conception and third trimester HbA1c values were 62mmol/mol 
(IQR=51-76) and 50mmol/mol (IQR=43-58) respectively. The median gestational age at delivery was 37 weeks 
(IQR=36-38) and 38% were delivered preterm (<37 weeks). 
 
Maternal pre-existing diabetes and the risks of fetal and infant death 
46 fetal deaths (including five late miscarriages, 38 antepartum stillbirths and three intrapartum stillbirths) and 
ten infant deaths (including six neonatal deaths and four post-neonatal deaths) were observed in women with pre-
existing diabetes. The prevalence of fetal death in women with pre-existing diabetes was 29.7 (95% CI: 21.8, 
39.4) per 1,000 deliveries, over four times greater than among those without [RR=4.56 (95% CI: 3.42, 6.07) 
p<0.0001] (Table 1). The prevalence of fetal death was not significantly different between women with type 1 
diabetes [28.2 (19.6, 39.2) per 1,000 deliveries] and women with type 2 diabetes [35.1 (18.3, 60.5) per 1,000 
deliveries] (p=0.51). Significantly increased risks were observed for both antepartum stillbirths [RR=6.10, (4.44, 
8.38) p<0.0001) and intrapartum stillbirths [RR=3.97 (1.27, 12.41) p=0.042). The estimated RR for a preterm 
fetal loss [RR=4.95 (3.59, 6.82) p<0.0001] was almost identical to that for a term stillbirth [RR=5.05 (2.62, 9.71) 
p<0.0001], although the RR for a late miscarriage was significantly smaller [RR=1.61 (0.67, 3.86) p=0.25] (Table 
2). The prevalence of infant death in women with pre-existing diabetes was 6.7 (3.2, 12.2) per 1,000 live births, 
almost two times greater than among those without [RR=1.86 (1.00, 3.46) p=0.046] (Table 1). The prevalence of 
infant death was not significantly different between women with type 1 diabetes [7.7 (3.5, 14.5) per 1,000 live 
births] and women with type 2 diabetes [3.0 (0.8, 16.8) per 1,000 deliveries] (p=0.70). 
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Although the prevalence of fetal and infant death declined from 11.4 (10.8, 12.0) per 1,000 deliveries in 1996-
1999 to 9.3 (8.8, 9.9) per 1,000 deliveries in 2005-2008 (p<0.0001), there was no change in the RR associated 
with diabetes [in 1996-1999: RR=4.5 (2.8, 7.0), in 2005-2008: RR=4.3 (2.8, 6.4)] (p=0.95). 
 
HbA1c and the odds of fetal and infant death 
Increasing peri-conception HbA1c for values above 49mmol/mol (6.6%) [adjusted OR, aOR per mmol/mol=1.02 
(95% CI: 1.00, 1.04) p=0.01], pre-pregnancy retinopathy [aOR=2.05 (1.04, 4.05) p=0.04] and lack of pre-
pregnancy folic acid consumption [aOR=2.52 (1.12, 5.65) p=0.03] were all independently associated with 
increased odds of fetal and infant death (Supplementary Table 3). Maternal smoking during pregnancy was also 
crudely associated with the risk of fetal and infant death [OR=1.91 (1.08, 3.36) p=0.03], but the association was 
not apparent after adjustment for peri-conception HbA1c and folic acid consumption [aOR=1.54 (0.80, 2.94) 
p=0.19]. There was no evidence that the effects of peri-conception HbA1c, pre-pregnancy retinopathy, or lack of 
pre-pregnancy folic acid consumption on the risk of fetal and infant death were different in women with type 2 
diabetes compared with women with type 1 diabetes (p=0.85, p=0.24, and p=0.74 respectively). In later 
pregnancy, increasing third-trimester HbA1c for values above 43mmol/mol [aOR=1.06 (1.03, 1.09) p<0.001] and 
lack of pre-pregnancy folic acid consumption [aOR=3.01 (1.03, 8.79) p=0.04] were the only variables that were 
significantly associated with the odds of a late stillbirth or infant death (Supplementary Table 3). 
 
When fetal and infant death were examined individually, increasing peri-conception HbA1c for values above 
49mmol/mol (6.6%) was the only variable that was significantly associated with either fetal death [OR=1.02 (1.01, 
1.04) p=0.01] or infant death [OR=1.03 (1.00, 1.06) p=0.01]. The association between peri-conception HbA1c and 
the odds of fetal death followed a J-shaped pattern (Figure 2), although the inverse association for values below 
49mmol/mol (6.6%) was not statistically significant [OR=0.95 (0.86, 1.05) p=0.31].  
 
The estimated absolute risks of fetal death, stillbirth, late stillbirth, and infant death (overall and by peri-
conception and third trimester HbA1c) are reported in Table 3. 
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Discussion 
Principal findings 
This large population-based study describes the association between pre-existing diabetes and measures of 
glycaemic control and the risks of fetal and infant death in normally-formed singleton offspring. The prevalence 
of fetal death (3%) was over four times greater among women with pre-existing diabetes while the prevalence of 
infant death (0.7%) was nearly doubled. There was no evidence that the RR of fetal and infant death associated 
with pre-existing diabetes had reduced over time, nor that the RR of stillbirth varied by gestational age, although 
the RR was smaller for late miscarriages.  
  
Among women with pre-existing diabetes, increasing peri-conception HbA1c (for values above 45mmol/mol), 
history of retinopathy and lack of pre-pregnancy folic acid consumption were all associated with increased odds 
of fetal and infant death. Peri-conception HbA1c was also associated with increased odds of fetal and infant death 
individually, with each 1mmol/mol increase [above 49mmol/mol (6.6%)] conferring a 2% and 3% relative 
increase respectively. The association between HbA1c and the odds of fetal death appeared to follow a J-shaped 
pattern. 
 
There was no difference in the risk of fetal and/or infant death among women with type 1 diabetes compared with 
those with type 2, nor was there any evidence that the associations with HbA1c, folic acid consumption, or history 
of retinopathy were different between types. 
 
Strengths and limitations 
This study, describing one of the largest obstetric cohorts of women with pre-existing diabetes, benefits from the 
North of England's long history of collaboration between maternity and neonatal services, which created and 
maintains several complementary population-based registers. Detailed information was collected prospectively 
on a range of clinical and socio-demographic variables, including multiple measures of HbA1c. All late 
miscarriages, stillbirths and infant deaths in the region, regardless of whether they occurred in women with 
diabetes, were obtained from an established register of fetal and infant mortality, minimising the risk of bias from 
disparities in ascertainment. By excluding all cases with major congenital anomaly derived from an independent 
and long-standing population-based register (which should again be robust to disparities in ascertainment); this 
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study is novel in describing the associations in normally-formed offspring. The results are likely to be 
generalizable to any predominately white population with similar standards of peri-conception and perinatal care. 
 
Several limitations result from low statistical power. Only six neonatal deaths, four post-neonatal deaths and three 
intrapartum stillbirths were identified, preventing these events from being analysed with precision. For most 
analyses, fetal and infant deaths were combined, despite likely differences in aetiologies[23]. Due to instability at 
the tails of our LOWESS models, we only report absolute risks for the middle 90% of values of HbA1c. The 
primary PXOWLYDULDWHDQDO\VHVKDGDGHTXDWHSRZHUȕ WRGHWHFWa 'medium effect' (&RKHQ¶VG, equivalent 
WRDQ25RI) for any variable with a baseline exposure probability of 14%-65%. Weaker associations, or 
associations in exposures outside this range, may therefore have been missed.  
 
Our LOWESS models, unlike our regression models, made no account for the non-independence of repeat 
pregnancies occurring within the same woman, introducing a potential source of error. For each regression model, 
however, the addition of the between-mother intercept did not significantly improve the model and only 
engendered negligible changes in the other coefficients, suggesting any bias is likely to be trivial.  
 
Pre-conception HbA1c was missing for half the cohort, reflecting low attendance for preconception care. We 
therefore used a composite measure of peri-conception HbA1c as a proxy for pre-conception HbA1c. Although first 
trimester values correlate highly with pre-conception, this may have introduced random error. HbA1c itself is an 
imperfect measure of glycaemic control as it provides no information on glycaemic excursions or hypoglycaemic 
episodes[27], which may be important in the aetiopathology of fetal and/or infant death[28]. Continuous glucose 
monitoring provides a more complete record of day to day glycaemic control but is not routinely used in the UK. 
No information was recorded on pharmacological treatments, so we could not explore their possible contribution. 
Since the PMMS does not collect information on miscarriages before 20 weeks, we were not able to examine the 
RR of earlier fetal losses, the risks of which may also be raised in women with diabetes. Finally, although the 
PMMS records cause of death, over half of all deaths were attributed simply to 'maternal disorder', preventing us 
from exploring whether diabetes was associated with any particular cause.  
 
Comparison with other studies 
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Flenady et al conducted an abridged meta-analysis, including just four studies, which estimated that RR of 
stillbirth was around three times higher in women with diabetes than among those without [OR=2.90 (2.05, 4.09)]. 
This is smaller than our estimates for both fetal death [OR=4.56 (3.42, 6.07)] and stillbirth [OR=5.87 (4.32, 
7.97)][5]. The largest study to examine the RR of fetal death is Mondestrin et al's analyses of data from the US 
natality and mortality surveys during 1995-1997[9]. Describing 271,691 pregnancies complicated by diabetes and 
excluding births with recorded congenital anomalies, they reported an RR for fetal death of 2.0 (1.8, 2.2)[9], less 
than half our estimate. This may be because Mondestrin et al did not distinguish between pre-existing and 
gestational diabetes or may reflect ascertainment deficiencies inherent in using birth certificate data[9]. Recent 
data from Ontario describing deliveries from 2005-2006 showed an even smaller RR for stillbirth of 1.53 (0.88, 
2.63) for pre-existing diabetes, although they also found an implausible protective effect for gestational diabetes 
[RR=0.33 (0.12, 0.71)][10]. In a large cohort from Australia including 433,379 deliveries from 1998-2002, 
Mohsin et al reported a similarly small RR of 1.87 (1.01, 3.48)[11], although it was not indicated how diabetes 
was defined or ascertained.  
 
There is more agreement between studies from Northern Europe, which typically report RRs of four to five times 
for stillbirth and two to four times for neonatal/infant death. In a large study of women with type 1 diabetes from 
Sweden during 1991-2003, Persson et al reported ORs of 4.04 (3.02, 5.40) and 3.08 (2.02, 4.70) for late stillbirth 
and neonatal death respectively[12], while Jensen et al's study from Denmark during 1993-1999, reported 
corresponding RRs of 4.72 (3.18, 7.01) and 3.40 (1.91, 6.07)[13]. Eidem et al's study from Norway during 1985-
2004 reported smaller, though not statistically inconsistent, ORs of 3.6 (2.5, 5.3) and 1.9 (1.1, 3.2) 
respectively[14]. Four studies from the UK reported strikingly similar results, possibly reflecting the increased 
homogeneity of care[15-18]. The four RR estimates for stillbirth ranged between 4.39 (2.22, 8.64) and 4.7 (3.7, 
6.0)[15-18], while the two estimates of neonatal death were 2.4 (1.4, 4.1) and 2.6 (1.7, 3.9)[15, 17]. 
 
Eidem et al and dos Santos Silva et al examined whether the RR of stillbirth associated with diabetes varied by 
gestational age, both reporting that the effect was confined to term deliveries[14, 15]. In contrast, we found the 
RR of stillbirth was uniformly raised for all gestational ages. This discrepancy is due to different methodological 
approaches. Eidem et al and dos Santos Silva et al used the traditional method of calculating stillbirth rate per 
deliveries in that period[14, 15], an approach that is highly susceptible to confounding by differences in gestational 
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age distribution. The rate of induced preterm birth is considerably higher among women with diabetes than among 
those without.[29] This shift in the denominator produces an artifactually smaller stillbirth rate during preterm 
(and a larger one during term). By offsetting against the total population of fetuses at risk of fetal death at a 
particular gestational age, rather than simply the sample of deliveries at that gestational age, our findings are 
robust to this problem[23]. 
 
Few studies have described the continuous association between HbA1c and the risk of fetal and/or infant death. 
Using LOWESS, Nielsen et al demonstrated an approximately linear association between increasing first-
trimester HbA1c above 53mmol/mol and the risk of 'adverse outcome', although this included congenital anomalies 
and elective terminations[30]. In women with type 1 diabetes, Jensen et al found that the RR of perinatal mortality 
increased steadily from 2.8 (1.3, 6.1) to 7.3 (2.5, 19.8) as peri-conception HbA1c increased from <52mmol/mol to 
>90mmol/mol respectively[31]. Neither Nielsen et al nor Jensen et al specifically examined whether low values 
of HbA1c were potentially harmful[30, 31], although Nielsen et al's LOWESS curve showed evidence of the same 
J-shape observed in our study[30]. 
 
The association between retinopathy, or any microvascular complication, and the risk of fetal or infant death in 
women with diabetes has not been well described. Contrasting with the current study, Jensen et al found no 
significant difference (p=0.58) in the rate of 'serious adverse outcome' (perinatal death and/or congenital anomaly) 
between women with and without retinopathy[13], although the proportion diagnosed with retinopathy was 
considerably smaller than in our cohort. In a previous study in women with diabetes in the North of England, 
nephropathy, but not retinopathy, was associated with an increased risk of congenital anomalies[2].  
 
To our knowledge, this is the first study to explore the association between pre-pregnancy folic acid and the risk 
of fetal and infant death in women with diabetes. However, in a mixed population from England, during 2009-
2011, Gardosi et al also identified a lower risk of stillbirth among women who had taken antenatal folic acid[32].  
 
Implications and Conclusions 
In England, the National Institute for Health and Clinical Excellence (NICE) recommends that women with pre-
existing diabetes aim for a pre-conception HbA1c below 43mmol/mol (6.1%)[19]. The American Diabetes 
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Association (ADA) suggest 53mmol/mol (7%)[20]. Our results strongly support the attainment and maintenance 
of good glycaemic control before and throughout pregnancy. If the average peri-conception HbA1c had been 
53mmol/mol (the ADA target), rather than 62mmol/mol, then our estimates suggest the prevalence of fetal and 
infant death would have been 38% lower. However, we found evidence of a J-shaped association between HbA1c 
and the risk of fetal death. Although implausible that euglycaemic levels of HbA1c are harmful, it is possible that 
hypoglycaemic episodes, which are more common in women with diabetes and low HbA1c[33], may be[28]. At 
the least, our results show that for fetal deaths, as for congenital anomalies[2], there appears to be no substantive 
benefit of achieving peri-conception levels below the ADA target. At the other extreme, NICE discourages 
pregnancy when the pre-conception HbA1c is above 86mmol/mol (10%)[19]. In demonstrating a clear continuum 
in risk above 53mmol/mol, our results provide no evidence for this specific threshold. 
 
Even in women with optimal peri-conception HbA1c [with values of 49mmol/mol (6.6%)], we estimated the risk 
of fetal death to be over twice as high as among women without diabetes [16.6 (8.6, 26.8) vs 6.5 (6.3, 6.8) per 
1,000 deliveries]. This may reflect the limitations of HbA1c as a marker of glycaemic control, or it may suggest 
that other risk factors are operating in women with diabetes.  
 
The rate of fetal and infant death was over two times higher among women who did not take pre-pregnancy folic 
acid supplements. Women with pre-existing diabetes are advised to take high doses (5mg/day) of folic acid 
specifically 'to reduce the risk of having a baby with a neural tube defect'[19]. Our results suggest there may be 
additional benefits for normally-formed offspring, although folic acid use may also simply indicate better 
preparation for pregnancy. 
 
History of retinopathy was associated with a doubling in the risk of fetal and infant death. It is possible that 
retinopathy indicates a prolonged history of poor glycaemic control that is not adequately described by HbA1c, or 
it may signify wider microvascular deficiencies that might impair placental development. These women may 
warrant additional support when planning their pregnancy. 
 
Over twenty years after the St Vincent declaration, we found that the excess risk of fetal and infant death in women 
with diabetes has remained stubbornly persistent. In the North of England, less than half of women with pre-
 16 
existing diabetes attend pre-conception care, with the proportion declining over time[34]. To achieve any 
reduction in the RR of stillbirth and infant death in women with pre-existing diabetes, the barriers to uptake of 
pre-conception care and adequate preparation for pregnancy must be urgently understood and addressed.  
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Tables 
Table 1 Relative risk of a fetal or infant death (in normally-formed singleton offspring) associated with maternal pre-
existing diabetes in the North of England during 1996-2008.  
 
Outcome 
Without pre-existing diabetes With pre-existing diabetes 
Relative risk 
(95% CI) p-value 
Cases 
(N=395,844a / 
393,262b) 
Prevalence (95% CI), per 
1,000 deliveriesc / live 
birthsd 
Cases 
(N=1548a / 
1502b) 
Prevalence (95% CI), per 
1,000 deliveriesc / live 
birthsd 
Fetal or infant death 3988 10.1 (9.8, 10.4) 56 36.2 (27.4, 46.7) 3.59 (2.77, 4.65) p<0.0001 
   Fetal deathe 2582 6.5 (6.3, 6.8) 46 29.7 (21.8, 39.4) 4.56 (3.42, 6.07) p<0.0001 
      Late miscarriagef 796 2.0 (1.9, 2.2) 5 3.2 (1.0, 7.5) 1.61 (0.67, 3.86) p=0.25m 
      Stillbirthg 1786 4.5 (4.3, 4.7) 41 26.5 (19.1, 35.8) 5.87 (4.32, 7.97) p<0.0001 
         Antepartum stillbirthh 1593 4.0 (3.8, 4.2) 38 24.5 (17.4, 33.5) 6.10 (4.44, 8.38) p<0.0001 
         Intrapartum stillbirthi 193 0.5 (0.4, 0.6) 3 1.9 (0.4, 5.7) 3.97 (1.27, 12.41) p=0.042m 
   Infant deathj 1406 3.6 (3.4, 3.8) 10 6.7 (3.2, 12.2) 1.86 (1.00, 3.46) P=0.046 
      Neonatal deathk 904 2.3 (2.1, 2.5) 6 4.0 (1.5, 8.7) 1.74 (0.78, 3.87) p=0.17m 
      Post-neonatal deathl 502 1.3 (1.2, 1.4) 4 2.7 (0.7, 6.8) 2.09 (0.78, 5.57) p=0.13m 
 
aTotal singleton live births, stillbirths and late miscarriages. bTotal singleton live births. cThe prevalence of fetal or infant 
death, and fetal death and all subsidiary outcomes of fetal death are presented per 1,000 deliveries. dThe prevalence of infant 
death and all subsidiary outcomes are presented per 1,000 live births. eLate miscarriages and stillbirths. fSpontaneous loss 
of a fetus at 20-23 completed weeks of gestation. gDeliveries of a fetus showing no signs of life at 24 or more completed 
weeks of gestation. hStillbirths where the fetus died before the onset of labour. iStillbirths where the fetus died after the 
onset of labour. jNeonatal deaths and post-neonatal deaths. kDeath, following live birth, within the first 28 days of life. 
lDeath, following live birth, of an infant aged 28 days or more, but less than one year. mFisher's exact test. 
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Table 2 Absolute and relative risks of a fetal death (in normally-formed singleton offspring) associated with maternal pre-
existing diabetes, by gestational age.   
 
Gestational age Fetal deaths Total deliveries On-going pregnancies 
Risk during given gestational age (95% CI) 
Absolute risk (per 1,000 deliveries) Relative risk Compared with  RR at term 
Pre-existing diabetes: With Without With Without With Without With Without   
Preterm (20-36 weeks) 37 1913 585 34618 1548 395844 23.9 (16.9, 32.8) 4.8 (4.6, 5.1) 4.95 (3.59, 6.82) 0.98 (0.47, 2.04) 
   20-23 weeks 5 796 6 796a 1548 395844 3.2 (1.0, 7.5) 2.0 (1.9, 2.2) 1.61 (0.67, 3.86) 0.32 (0.11, 0.95) 
   24-27 weeks 10 413 15 4828 1542 395048 6.5 (3.1, 11.9) 1.0 (0.9, 1.2) 6.20 (3.32, 11.59) 1.23 (0.50, 3.05) 
   28-36 weeks 22 704 564 28994 1527 390220 14.4 (9.1, 21.7) 1.8 (1.7, 1.9) 7.99 (5.24, 12.17) 1.58 (0.72, 3.46) 
Term (37-41 weeks) 9 669 963 361226 963 361226 9.3 (4.3, 17.7) 1.9 (1.7, 2.0) 5.05 (2.62, 9.71) 1 (reference) 
Total 46 2582 1548 395844 1548 395844 29.7 (21.8, 39.4) 6.5 (6.3, 6.8) 4.56 (3.42, 6.07)  
 
aBonellie et al[24] provides no estimate of the number of deliveries occurring during 20-23 weeks. This was approximated 
to be equal to the total number of fetal deaths during the same period. 
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Table 3 Absolute risk of a fetal or infant death (in normally-formed singleton offspring) in women with pre-existing diabetes, overall and by HbA1c peri-conception and in the third 
trimester.  
 
Outcome Risk, per 1,000 (95% CI) 
  By peri-conception HbA1c (mmol/mol, DCCT % in brackets)a 
  
40 ± 49 
(5.8 ± 6.6)  
50 ± 59 
(6.7 ± 7.5) 
60 ± 69 
(7.6 ± 8.5) 
70 ± 79 
(8.6 ± 9.4) 
80 ± 89 
(9.5 ± 10.3) 
90 ± 99 
(10.4 ± 11.2) 
c  
(6.1) 
d  
(7) 
e  
(10) 
49f 
(6.6) 
Fetal death  29.7 (21.8, 39.4) 
19.6 
(9.6, 33.6) 
19.3 
(11.9, 29.0) 
28.4 
(18.2, 40.6) 
36.5 
(24.2, 50.8) 
41.5 
(27.0, 58.3) 
44.8 
(26.4, 67.3) 
31.9 
(7.2, 64.8) 
22.7 
(9.5, 39.4) 
46.7 
(22.4, 79.41) 
16.6 
(8.6, 26.8) 
   Stillbirth 26.6
b
 
(19.1, 35.9) 
18.7 
(8.6, 31.6) 
17.5 
(10.3, 26.6) 
24.7 
(14.9, 36.0) 
30.9 
(19.3, 44.2) 
35.4 
(21.8, 51.1) 
39.2 
(21.6, 60.9) 
30.9 
(8.0, 64.7) 
21.7 
(9.3, 38.1) 
42.7 
(19.0, 74.2) 
15.5 
(7.8, 25.1) 
      Late stillbirth  20.3
b
 
(13.8, 28.7) 
13.0 
(4.9, 24.8) 
12.4 
(6.5, 20.3) 
17.5 
(9.9, 27.2) 
23.4 
(14.1, 34.9) 
28.7 
(16.7, 42.9) 
33.9 
(17.5, 53.6) 
21.8 
(3.0, 49.3) 
15.2 
(0.5, 29.0) 
38.9 
(16.0, 68.9) 
10.7 
(4.7, 19.0) 
 
B
y 
th
ird
 
tr
im
es
te
r 
H
bA
1c
 
(m
m
o
l/m
o
l, 
D
CC
T 
%
 in
 
br
ac
ke
ts
) 
35 ± 44 
(5.4 ± 6.2) 
10.3 
(4.3, 18.9) 
7.1 
(2.1-12.0) 
6.4 
(1.4-11.4) 
8.1 
(2.1-14.1) 
10.3 
(2.6-18.1) 
12.3 
(2.3-22.3) 
14.6  
(1.3-27.9) 
8.4  
(2.2-14.5) 
8.4 
(3.0, 13.9) 
19.2 
(2.2, 36.2) 
5.6 
(0.9, 10.4) 
 
45 ± 54 
(6.3 ± 7.1) 
13.4 
(7.0, 21.0) 
9.3 
(2.6, 15.9) 
8.3 
(2.4, 14.3) 
10.5 
(3.8, 17.2) 
13.3 
(5.0, 21.7) 
15.9 
(5.1, 26.7) 
18.8 
(4.2, 33.3) 
11.0 
(2.2, 19.9) 
11.0 
(3.7, 18.4) 
24.8 
(4.2, 45.3) 
7.3 
(1.5, 13.2) 
 
55 ± 64 
(7.2 ± 8.0) 
22.5 
(13.2, 33.4) 
16.1 
(4.8, 27.5) 
14.5 
(4.9, 24.1) 
18.3 
(8.5, 28.2) 
23.3 
(12.4, 34.2) 
27.8 
(14.4, 41.2) 
32.7 
(14.1, 51.4) 
19.1 
(3.8, 34.5) 
19.2 
(7.3, 31.1) 
45.5 
(15.4, 75.6) 
12.8 
(3.0, 22.6) 
 
65 ± 74 
(8.1 ± 8.9) 
 
39.8 
(21.6, 62.2) 
29.1 
(5.2, 53.0) 
26.2 
(6.4, 46.1) 
33.1 
(13.0, 53.2) 
42.0 
(21.2, 62.8) 
49.9 
(27.1, 72.8) 
58.6 
(29.5, 87.7) 
34.4 
(3.1, 65.6) 
34.5 
(9.5, 59.5) 
76.6 
(27.9, 125.3) 
23.2 
(3.1, 43.3) 
 
75 ± 84 
(9.0±9.8) 
 
72.9 
(26.4, 123.4) 
54.1 
(<0.1, 110.2) 
49.2 
(1.6, 96.7) 
61.9 
(10.8, 113.0) 
78.3 
(23.1, 133.6) 
92.8 
(33.7, 151.9) 
108.4 
(41.4, 175.4) 
63.3 
(<0.1, 133.1) 
63.8 
(3.9, 123.7) 
139.7 
(36.1, 243.3) 
43.6 
(<0.1, 90.2) 
 
43f 
(6.1) 
8.9 
(4.2, 15.4) 
6.3 
(1.2, 11.3) 
5.6 
(1.0, 10.3) 
7.1 
(1.5, 12.7) 
9.0 
(1.8, 16.2) 
10.7 
(1.5, 20.0) 
12.7 
(0.5, 24.8) 
7.5 
(0.9, 14.1) 
7.5 
(1.7, 13.3) 
16.8 
(0.2, 33.3) 
5.0 
(0.6, 9.3) 
Infant death 6.7  (3.2-12.2) No cases
g
 
4.3 
(1.0, 9.2) 
6.6 
(2.2, 12.5) 
8.8 
(3.3, 16.0) 
10.7 
(4.2, 20.4) 
13.3 
(4.4, 26.0) No cases
g
 No casesg 17.6 (4.0, 39.1) No casesg 
 
Fetal deaths, stillbirths, and late stillbirths DUHGHOLYHULHVRID IHWXV VKRZLQJQRVLJQVRI OLIHDWZHHNVRIJHVWDWLRQZHHNVRIJHVWDWLRQDQGZHHNVRIJHVWDWion 
respectively. Infant deaths are deaths, following live birth, within the first year of life. The absolute risks of fetal death, stillbirth, late stillbirth and infant death, overall and by 
selected values of peri-conception and third trimester HbA1c, were estimated by locally-weighted scatterplot smoothing (LOWESS) while the absolute risks of late stillbirth for 
selected values of peri-conception and third trimester HbA1c simultaneously, were estimated from logit-linked generalised estimating equations. 
 
aDefined as the closest measurement within three months prior to the last menstrual period or mean first trimester measurement (<14 weeks' gestation) for women with no pre-
conception measurement. bMinor discrepancies from Table 1 are due to very slightly different denominators. Table 1 presents the rates per all deliveries after 20 weeks; these values 
are per deliveries after 24 weeks (stillbirths) and 28 weeks (late stillbirths) specifically. cA pre-pregnancy HbA1c target RImmol/mol is recommended by the National Institute 
IRU&OLQLFDO([FHOOHQFHµIf it is safely achievable, women with diabetes who are planning to become pregnant should aim to maintain their HbA1c EHORZ¶[19] dA pre-pregnancy 
HbA1c target of PPROPROLVUHFRPPHQGHGE\WKHAmerican Diabetes Association: µ$&OHYHOVVKRXOGEHDVFORVHWRQRUPDODVSRVVLEOHLQDQLQGLYLGXDOSDWLHQWEHIRUH
FRQFHSWLRQLVDWWHPSWHG¶[20] eThe National Institute for Clinical Excellence advises that women with a pre-pregnancy HbA1c above 86mmol/mol should be advised to avoid 
 24 
pregnancy: µWomen with diabetes whose HbA1c is above 10% should be strongly advised to avoid pregnancy.¶[19] fThe peri-conception and third-trimester HbA1c values with the 
lowest risks of fetal death or late stillbirth were estimated to be 49mmol/mol (6.6%) and 43mmol/mol (6.1%) respectively. LOWESS estimates for these values were obtained by 
averaging each LOWESS curve within ±1mmol/mol of the target value gThere were no cases of infant death among women with a peri-conception HbA1c below 53mmol/mol, thus 
the estimated risk for these categories are not reported. 
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Figures 
Figure 1. Derivation of the study sample. 
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Figure 2. Peri-conception glycated haemoglobin (HbA1c) and risk of fetal or infant death in women with pre-existing 
diabetes. 
 
Fetal deaths (red), stillbirths (blue), and late stillbirths (green) DUHGHOLYHULHVRIDIHWXVVKRZLQJQRVLJQVRIOLIHDW
ZHHNVRIJHVWDWLRQZHHNVRIJHVWDWLRQDQGZHHNVRIJHVWDWLRQUHVSHFWLYHO\Infant deaths (orange) are deaths, 
following live birth, within the first year of life. aA pre-pregnancy HbA1c WDUJHWRIPPROPROLVUHFRPPHQGHGE\WKH
1DWLRQDO ,QVWLWXWHIRU&OLQLFDO([FHOOHQFHµIf it is safely achievable, women with diabetes who are planning to become 
pregnant should aim to maintain their HbA1c EHORZ ¶[19] bA pre-pregnancy HbA1c WDUJHW RI PPROPRO LV
recommended by the American Diabetes Association: µ$&OHYHOVVKRXOGEHDVFORVHWRQRUPDODVSRVVLEOHLQDQ
individual patient before conceptioQLVDWWHPSWHG¶[20] cThe National Institute for Clinical Excellence advises that women 
with a pre-pregnanF\+E$FDERYHPPROPROVKRXOGEHDGYLVHGWRDYRLGSUHJQDQF\µWomen with diabetes whose HbA1c 
is above 10% should be strongly advised to avoid pregnancy.¶[19] 
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